Member LoginDividend CushionValue Trap |
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for
any changes.
Jul 31, 2017
Newsletter Notifications -- July 31
We are making a number of changes to the newsletter portfolios today, July 31. Jul 31, 2017
A Review of Johnson and Johnson’s Pharmaceutical Division
Image Source: J&J. Let’s take a deep dive into Johnson and Johnson’s pharmaceutical division Janssen Pharmaceuticals. Janssen traditionally serves as an area of clinical innovation adding an element of growth to the more stable product categories such as consumer health. However, there may be a few cracks in the Janssen revenue stream that could make growth at J&J harder to come by over the next few years. Jul 31, 2017
Amgen’s Pipeline Continues to Disappoint
Image Source: Amgen. The ability to generate commercially-viable products via the clinical pipeline is crucial to grow profits and offset revenue declines from the loss of patent protection. We remain unimpressed with the progress shown thus far by biotech stalwart Amgen. Let’s review the clinical pipeline along with a consideration of the recently-released earnings report. Jul 31, 2017
Alphabet’s Financial Health Unfazed By European Commission Fine
Image Source: Open Grid Scheduler. Alphabet’s second-quarter results revealed a one-time charge that made headlines, but the fine is a drop in the bucket when considering the size of Google’s balance sheet and free cash flow generation. Jul 30, 2017
Dividend Increases/Decreases for the Week Ending July 28
Let's take a look at companies raising/lowering their dividends this week. Jul 28, 2017
Altria Keeps Smoking; Is Smokeless the Future for Big Tobacco?
Tobacco giant Altria reported another solid quarter thanks in large part to its pricing power, but big tobacco may be altering its strategy as it finds an unexpected ally. Jul 27, 2017
Hasbro Hit by Gross Margin, Timing Issues
Shares of Dividend Growth Newsletter portfolio holding Hasbro dropped after the company reported its second quarter earnings. We're watching shares closely. Jul 26, 2017
Boeing’s Shares Rocketing Higher
Image Source: Rob Bulmahn. Dividend Growth Newsletter portfolio holding Boeing issued second-quarter results and raised full-year 2017 guidance. We remain bullish on the commercial aerospace supply chain and defense contractors amid increasing geopolitical tensions across the globe. Jul 25, 2017
Stocks in the News: Kinder Morgan, Union Pacific, Colgate-Palmolive
Let’s cover the quarterly reports from a few industry bellwethers. Jul 21, 2017
Stocks in the News: Visa, Microsoft, General Electric
Image source: Visa. Let’s have a look at the quarterly reports from a few stocks in the news July 21.
prev12345678910111213141516171819202122232425
26272829303132333435363738394041424344454647484950 51525354555657585960616263646566676869707172737475 767778798081828384858687888990919293949596979899100 101102103104105106107108109110111112113114115116117118119120 121122123124125126127128129130131132133134135136137138139140 141142143144145146147148149150151152153154155156157158159160 161162163164165166167168169170171172173174175176177178179180 181182183184185186187188189190191192193194195196197198199200 201202203204205206207208209210211212213214215216217218219220 221222223224225226227228229230231232233234235236237238239240 241242243244245246247248249250251252253254255256257258259260 261262263264265266267268269270271272273274275276277278279280 281282283284285286287288289290291292293294295296297298299300 301302303304305306307308309310311312313314315316317318319320 321322323324325326327328329330331332333334335336337338339340 341342343344345346347348349350351352353354355356357358359360 361362363next The High Yield Dividend Newsletter, Best Ideas
Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on
this website are for information purposes only and should not be considered a solicitation to buy or sell any
security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s
accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or
omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts
no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a
registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees,
and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.
|